Author

Beili Gao

Observed names: BEI-LI GAO, Bei-Li Gao, Bei-li Gao

Institutions: Shanghai Jiao Tong University, Ruijin Hospital

Observed institutions: Shanghai Jiao Tong University, Sichuan University, Ruijin Hospital, West China Hospital of Sichuan University, First Affiliated Hospital of Guangzhou Medical University, Zhejiang Cancer Hospital, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health

OpenAlex ID: A5112622965

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

2022 · Zhijie Wang, Lin Wu, et al. · Journal of Clinical Oncology · 182

PDF

PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients

2021 · Ran Zeng, Fang Liu, et al. · Frontiers in Immunology · 78

Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial

2023 · Caicun Zhou, Gongyan Chen, et al. · Journal of Thoracic Oncology · 75

PDF

Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy

2019 · Xiaofei Wang, Ling Zhou, et al. · Journal of Thoracic Oncology · 57

PDF

Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study

2021 · Xinghao Ai, Yueyin Pan, et al. · Journal of Thoracic Oncology · 56

International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease

2023 · Chengzhi Zhou, Yinyin Qin, et al. · Translational Lung Cancer Research · 39

PDF

Impact of Angiotensin I-converting Enzyme Inhibitors and Angiotensin II Type-1 Receptor Blockers on Survival of Patients with NSCLC

2016 · Lili Miao, Wei Chen, et al. · Scientific Reports · 35

PDF

Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study

2024 · Caicun Zhou, Gongyan Chen, et al. · Journal for ImmunoTherapy of Cancer · 33

PDF

Monitoring antiangiogenesis of bevacizumab in zebrafish

2018 · Jing Zhang, Beili Gao, et al. · Drug Design Development and Therapy · 27

PDF

Pulmonary enteric adenocarcinoma with pancreatic metastasis: A case report

2017 · Wen-Wen Sun, Zhi-Hong Xu, et al. · Oncology Letters · 19

PDF

Gefitinib, an EGFR tyrosine kinase inhibitor, activates autophagy through AMPK in human lung cancer cells.

2014 · Zhihong Xu, Junbiao Hang, et al. · PubMed · 18

Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study

2022 · Jin Yang, Ran Zeng, et al. · Translational Lung Cancer Research · 17

PDF

Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 Study

2021 · Xinghao Ai, Qiming Wang, et al. · Journal of Thoracic Oncology · 17

PDF

Metformin sensitizes lung cancer cells to treatment by the tyrosine kinase inhibitor erlotinib

2017 · Xiaofei Wang, Keqiang Chen, et al. · Oncotarget · 16

PDF

Posttranslational modifications of FOXO1 regulate epidermal growth factor receptor tyrosine kinase inhibitor resistance for non-small cell lung cancer cells

2015 · Zhi-hong Xu, Wen-wen Shun, et al. · Tumor Biology · 16

Genetic polymorphisms of XPD and CDA and lung cancer risk

2012 · MIN ZHOU, HUAN-YING WAN, et al. · Oncology Letters · 16

PDF

Chinese expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2022 edition)

2023 · Jianchun Duan, Wenfeng Fang, et al. · Journal of the National Cancer Center · 11

Case Report: A 91-Year-Old Patient With Non-Small Cell Lung Cancer Harboring MET Y1003S Point Mutation

2022 · Beili Gao, Ran Zeng · Frontiers in Medicine · 9

Genomic landscape and evolution of arm aneuploidy in lung adenocarcinoma

2021 · Beili Gao, Fujun Yang, et al. · Neoplasia · 9

Imperatorin Targets MCL-1 to Sensitize CD133+ Lung Cancer Cells to γδ-T Cell-Mediated Cytotoxicity

2018 · Changxuan You, Yu Yang, et al. · Cellular Physiology and Biochemistry · 8

Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status

2017 · Hong Jian, Wei Li, et al. · Scientific Reports · 8

PDF

Significance of NLDA, the commixed index of inflammation, immune responses, hemostasis, and nutrition, for predicting metastatic non-small cell lung cancer prognosis and metastases

2017 · Wen-wen Sun, Jia-an Hu, et al. · Oncotarget · 6

Risk factors and prognostic role of renal adverse event in patients receiving immune checkpoint inhibitor therapy: analysis of data from a retrospective cohort study

2022 · Zhiyao Bao, Lifeng Luo, et al. · Annals of Translational Medicine · 5

PDF

Rituximab effectively reverses Tyrosine kinase inhibitors (TKIs) resistance through inhibiting the accumulation of rictor on mitochondria-associated ER-membrane (MAM)

2017 · Zhi-Hong Xu, Cai-Hong Liu, et al. · Cancer Biomarkers · 5

SDH mutations, as potential predictor of chemotherapy prognosis in small cell lung cancer patients

2023 · Ran Zeng, Xiaoyun Fan, et al. · Discover Oncology · 3

PDF

Works count: 37

Citation count: 776

H-index: 16

I10-index: 17